Drug Profile
DL 06002
Alternative Names: DL06002Latest Information Update: 26 Jul 2007
Price :
$50
*
At a glance
- Originator DanioLabs
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperhidrosis
Most Recent Events
- 03 Jul 2006 Phase-I clinical trials in Hyperhidrosis in United Kingdom (unspecified route)
- 03 Jul 2006 DanioLabs has initiated enrolment in a phase I trial for hyperhidrosis in the UK